| Literature DB >> 31593530 |
Md Tanvir Kabir1, Md Sahab Uddin2,3, Mst Marium Begum4, Shanmugam Thangapandiyan5, Md Sohanur Rahman6, Lotfi Aleya7, Bijo Mathew8, Muniruddin Ahmed9, George E Barreto10, Ghulam Md Ashraf11,12.
Abstract
In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dysfunction and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs which are under development and their respective mechanisms of actions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Acetylcholine; Alzheimer’s disease; acetylcholinesterase inhibitors; donepezil; galantamine; rivastigmine; tacrine.
Mesh：
Substances：
Year: 2019 PMID： 31593530 DOI： 10.2174/1381612825666191008103141
Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116